Atsuko Ochida

Fujisawa, 2518555, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Discovery of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 Main Protease through Computer-Aided Drug Design.

Discovery of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 Main Protease through Computer-Aided Drug Design.

Journal: Journal of medicinal chemistry
Published: October 12, 2025

High-throughput screening of small-molecules libraries identified antibacterials against clinically relevant multidrug-resistant A. baumannii and K. pneumoniae.

High-throughput screening of small-molecules libraries identified antibacterials against clinically relevant multidrug-resistant A. baumannii and K. pneumoniae.

Journal: EBioMedicine
Published: December 11, 2023

Collaborative Virtual Screening Identifies a 2-Aryl-4-aminoquinazoline Series with Efficacy in an In Vivo Model of Trypanosoma cruzi Infection.

Collaborative Virtual Screening Identifies a 2-Aryl-4-aminoquinazoline Series with Efficacy in an In Vivo Model of Trypanosoma cruzi Infection.

Journal: Journal of medicinal chemistry
Published: January 06, 2023

Partnership Activity for Neglected Tropical Diseases

Partnership Activity for Neglected Tropical Diseases

Journal: Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
Published: July 05, 2022

Discovery and Structure-Activity Relationships of Quinazolinone-2-carboxamide Derivatives as Novel Orally Efficacious Antimalarials.

Discovery and Structure-Activity Relationships of Quinazolinone-2-carboxamide Derivatives as Novel Orally Efficacious Antimalarials.

Journal: Journal of medicinal chemistry
Published: August 26, 2021

Repositioning and Characterization of 1-(Pyridin-4-yl)pyrrolidin-2-one Derivatives as Plasmodium Cytoplasmic Prolyl-tRNA Synthetase Inhibitors.

Repositioning and Characterization of 1-(Pyridin-4-yl)pyrrolidin-2-one Derivatives as Plasmodium Cytoplasmic Prolyl-tRNA Synthetase Inhibitors.

Journal: ACS infectious diseases
Published: April 30, 2021

Nonbisphosphonate inhibitors of Plasmodium falciparum FPPS/GGPPS.

Nonbisphosphonate inhibitors of Plasmodium falciparum FPPS/GGPPS.

Journal: Bioorganic & medicinal chemistry letters
Published: December 03, 2020

Design and Synthesis of Conformationally Constrained RORγt Inverse Agonists.

Design and Synthesis of Conformationally Constrained RORγt Inverse Agonists.

Journal: ChemMedChem
Published: July 12, 2019

Optimization of Methionyl tRNA-Synthetase Inhibitors for Treatment of Cryptosporidium Infection.

Optimization of Methionyl tRNA-Synthetase Inhibitors for Treatment of Cryptosporidium Infection.

Journal: Antimicrobial agents and chemotherapy
Published: October 02, 2018

Discovery of [ cis-3-({(5 R)-5-[(7-Fluoro-1,1-dimethyl-2,3-dihydro-1 H-inden-5-yl)carbamoyl]-2-methoxy-7,8-dihydro-1,6-naphthyridin-6(5 H)-yl}carbonyl)cyclobutyl]acetic Acid (TAK-828F) as a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor γt Inverse Agonist.

Discovery of [ cis-3-({(5 R)-5-[(7-Fluoro-1,1-dimethyl-2,3-dihydro-1 H-inden-5-yl)carbamoyl]-2-methoxy-7,8-dihydro-1,6-naphthyridin-6(5 H)-yl}carbonyl)cyclobutyl]acetic Acid (TAK-828F) as a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor γt Inverse Agonist.

Journal: Journal of medicinal chemistry
Published: March 07, 2018

Biochemical Properties of TAK-828F, a Potent and Selective Retinoid-Related Orphan Receptor Gamma t Inverse Agonist.

Biochemical Properties of TAK-828F, a Potent and Selective Retinoid-Related Orphan Receptor Gamma t Inverse Agonist.

Journal: Pharmacology
Published: January 25, 2018

Pharmacological inhibitory profile of TAK-828F, a potent and selective orally available RORγt inverse agonist.

Pharmacological inhibitory profile of TAK-828F, a potent and selective orally available RORγt inverse agonist.

Journal: Biochemical pharmacology
Published: November 14, 2017
Showing 1-12 of 15

Last Updated: 09/26/2026